Results of Skin Disposition Study to be Presented on September 10, 2015
MENLO PARK, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that data from its DRM01 acne program will be presented at the 45th Annual Meeting of the European Society for Dermatological Research (ESDR) being held September 9-12, 2015 in Rotterdam, Netherlands. The results of the study will be presented by Hans Hofland, Ph.D., vice president, research at Dermira.
The details of the presentation are as follows:
Title: Targeted delivery of DRM01, a novel, topical sebum inhibitor for the treatment of acne
Date and Time: September 10, 2015, at 6:30 to 8:30 p.m. CET (9:30 to 11:30 a.m. PDT) and September 12, 2015, at 11:30 a.m. to 1:00 p.m. CET (2:30 to 4:00 a.m. PDT)
Session: Epidermal Structure and Function
Location and Room: Postillion Convention Centre-WTC, outside main auditorium
Poster Number: 284
DRM01 is a novel, topical, small-molecule sebum inhibitor in development for the treatment of acne. Sebum is an oily substance made up of lipids produced by glands in the skin called sebaceous glands, and excessive sebum production is an important aspect of acne that is not addressed by available topical therapies. DRM01 is designed to exert its effect by inhibiting acetyl coenzyme-A carboxylase, an enzyme that plays an important role in the synthesis of fatty acids, a type of lipid that represents an essential component of the majority of sebum lipids. Based on the results of a 108-patient, randomized, multi-center, double-blind, vehicle-controlled Phase 2a clinical trial, Dermira commenced a Phase 2b clinical program in April 2015 and expects topline results from the Phase 2b clinical program in the first half of 2016.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, in Phase 3 development for the treatment of axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements that involve substantial risks and uncertainties, including with respect to the DRM01 mechanism of action and when results from the DRM01 Phase 2b clinical program will be available. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the outcomes of our clinical trials, our dependence on third-party clinical research organizations, manufacturers and suppliers, regulatory compliance with respect to the design and implementation of our clinical trials, our ability to obtain regulatory approval for our product candidates, and our ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled "Risk Factors" set forth in Dermira's Annual Report on Form 10-K, Dermira's Quarterly Report on Form 10-Q and other filings Dermira makes with the Securities and Exchange Commission from time to time for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this press release. We undertake no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
CONTACT: Dermira Contact
Chief Operating Officer and Chief Financial Officer
Robert H. Uhl